U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Trump Buys SpaceX Shares After Record IPO 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Tesla Raises Cybertruck Prices by $5,000 in US 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Add as a preferred source on Google
LEXINGTON, Mass. and LONDON, April 30, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8 at 4:10 p.m. ET in Boston, MA.
To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease.
For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.
Contacts:
Senthil Sundaram, Chief Financial Officer
Brian Luque, Sr. Manager, Investor Relations
[email protected]
